STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [Form 4] Spyre Therapeutics, Inc. Insider Trading Activity

Spyre Therapeutics, Inc. reported $0 in revenue and a $155.2M net loss for fiscal 2025. See the full SYRE financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Spyre Therapeutics director sells 80,000 shares

Spyre Therapeutics, Inc. director Michael Thomas Henderson reported open-market sales of a total of 80,000 shares of common stock on May 8, 2026.

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Michael Thomas Henderson reported open-market sales of a total of 80,000 shares of common stock on May 8, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026.

The sales were broken into four trades at weighted average prices between about $72.57 and $75.35 per share. Footnotes state that each reported price is a weighted average, with individual trades occurring in ranges from $72.03 up to $75.71 per share.

Positive

  • None.

Negative

  • None.
Insider HENDERSON MICHAEL THOMAS
Role Director
Sold 80,000 shs ($5.95M)
Type Security Shares Price Value
Sale Common Stock 2,404 $72.57 $174K
Sale Common Stock 33,513 $73.72 $2.47M
Sale Common Stock 24,814 $74.76 $1.86M
Sale Common Stock 19,269 $75.35 $1.45M
Holdings After Transaction: Common Stock — 88,606 shares (Direct)
Footnotes (5)
  1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.
  2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares sold 80,000 shares Total common stock sold on May 8, 2026
Weighted average price (highest block) $75.35 per share Open-market sale of 19,269 shares on May 8, 2026
Weighted average price (lowest block) $72.57 per share Open-market sale of 2,404 shares on May 8, 2026
Price range of trades (low) $72.03 per share Lowest individual execution price referenced in footnotes
Price range of trades (high) $75.71 per share Highest individual execution price referenced in footnotes
Trading plan adoption date February 6, 2026 Adoption date of Rule 10b5-1 trading plan governing sales
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale" and transaction_code_description: "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
non-derivative financial
"transaction_type: "non-derivative" for each common stock sale entry"

FAQ

What insider activity did Spyre Therapeutics (SYRE) disclose in this Form 4?
Spyre Therapeutics director Michael Thomas Henderson reported selling 80,000 shares of common stock in open-market transactions on May 8, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan and spread across four separate transactions.

How many Spyre Therapeutics (SYRE) shares did the director sell and at what prices?
The director sold 80,000 shares of Spyre Therapeutics common stock across four trades. Weighted average prices for the trades ranged from about $72.57 to $75.35 per share, with individual executions occurring between $72.03 and $75.71 according to the footnotes.

Was the Spyre Therapeutics (SYRE) insider sale made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. Such plans are pre-arranged trading programs that schedule future trades in advance, helping separate them from day-to-day market timing decisions.

What type of transactions did the Spyre Therapeutics (SYRE) Form 4 report?
All reported transactions were open-market sales of Spyre Therapeutics common stock, coded as “S” on the Form 4. The filing characterizes them as non-derivative transactions, meaning they involved direct common shares rather than options, warrants, or other derivative securities.

How many separate trades did the Spyre Therapeutics (SYRE) director execute?
The Form 4 lists four separate sale transactions on May 8, 2026. Each line reflects a block of shares sold at a weighted average price, with detailed price ranges for the underlying individual trades provided in the accompanying footnotes to the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HENDERSON MICHAEL THOMAS
(Last)(First)(Middle)
221 CRESCENT STREET, BUILDING 23,
SUITE 105
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026S(1)2,404D$72.57(2)166,202D
Common Stock05/08/2026S(1)33,513D$73.72(3)132,689D
Common Stock05/08/2026S(1)24,814D$74.76(4)107,875D
Common Stock05/08/2026S(1)19,269D$75.35(5)88,606D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks:
/s/ Heidy King-Jones, as Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR